Nectar Lifesciences announces ₹81 crore share buyback

Nectar Lifesciences Ltd. announced a public buyback of its equity shares totaling ₹81,00,00,000. The company plans to acquire up to 3,00,00,000 fully paid-up equity shares at a price of ₹27 per share. This buyback represents 13.38% of the total equity shares and 9.00% of the total paid-up equity share capital and free reserves as of March 31, 2025.

The buyback will be conducted through a tender offer via the stock exchange mechanism, on a proportionate basis. The record date for determining eligible shareholders is set for Wednesday, December 24, 2025. Promoters do not intend to participate in the buyback, ensuring their shares will not be considered for entitlement ratio calculations.

Nectar Lifesciences confirmed that the buyback will be funded from its securities premium account, free reserves, or other legally permitted sources, and no borrowed funds will be used. The company also affirmed its compliance with all regulatory provisions, including maintaining minimum public shareholding and not undertaking any other buyback in the past year.